Innovative Super Antibiotic Targets Gut Infection While Preserving Microbiome
Researchers in Leiden have developed EVG7, a potent low-dose antibiotic that effectively targets C. difficile infections while preserving beneficial gut bacteria, reducing relapse risk and potentially limiting resistance, with human trials possible in a few years.